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The risk of overanticoagulation in patients with heart failure on
coumarin anticoagulants
Coumarin anticoagulants are used in the primary and
secondary prophylaxis of thromboembolic disease (British
Committee for Standards in Haematology, 1998). They inhibit
the production of the vitamin K-dependent coagulation factors
by the liver (Sadowski et al, 1996). Inherent to their mode of
action and narrow therapeutic range, haemorrhage is the most
common adverse reaction to coumarin anticoagulants. The
risk of haemorrhage is strongly associated with the intensity of
anticoagulation and sharply increases when the international
normalized ratio (INR) ‡6Æ0 (Cannegieter et al, 1995; Van der
Meer et al, 1996). A number of comorbid conditions are
suspected to enhance the response to coumarin anticoagulants
(O’Reilly & Aggeler, 1970; Hirsh et al, 2001). Heart failure was
identified as a risk factor for increased coumarin responsive-
ness in some small-scale experiments (groups of up to 30
patients) in the late 1940s (Stats & Davison, 1949; Covert,
1952). The mechanism has not been fully elucidated but it is
speculated that increases in coumarin responsiveness are
associated with hepatic congestion and redistribution of body
fluids (Stats & Davison, 1949; Covert, 1952; Killip & Payne,
1960; O’Reilly & Aggeler, 1970; Bachmann & Shapiro, 1977).
Epidemiological studies quantifying the risk of overanticoa-
gulation by heart failure in a non-selected population on
coumarins are scarce. A recent case–control study suggested
that patients with heart failure had an increased risk of an INR
‡6Æ0 (Penning-van Beest et al, 2001). In that study, however,
the presence of chronic comorbidities was only based on the
diagnoses of general practitioners and no cases of incidental
heart failure were included. Therefore, we conducted a follow-
up study in a large population-based cohort among outpa-
tients of an anticoagulation clinic on acenocoumarol or
phenprocoumon. We studied the association between heart
failure and overanticoagulation and determined the effect of
heart failure on the coumarin dosage.
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Summary
Heart failure has been identified as a risk factor for increased
coumarin anticoagulant responsiveness in several small-scale experiments.
Epidemiological studies quantifying the risk of overanticoagulation by heart
failure in a non-selected population on coumarins are scarce. Therefore, we
investigated whether patients with heart failure have an increased risk of
overanticoagulation and determined the effect of incidental heart failure on
coumarin dose requirements. A cohort study of all patients was performed
from an outpatient anticoagulation clinic treated with acenocoumarol or
phenprocoumon between 1 January 1990 and 1 January 2000. All cohort
members were followed until the first occurrence of an international
normalized ratio (INR) ‡6Æ0, the last INR assessment, death, loss to follow-
up, or end of the study period. Of the 1077 patients in the cohort, 396
developed an INR ‡6Æ0. The risk of overanticoagulation was 1Æ66 [95%
confidence interval (CI): 1Æ33–2Æ07] for cases of prevalent heart failure and
1Æ91 (95%CI: 1Æ31–2Æ79) for incidental cases. The decrease in dose
requirements in patients with incidental heart failure showed a significant
trend from the fifth INR measurement preceding the date of incidental heart
failure to the third measurement after this date. Heart failure is an
independent risk factor for overanticoagulation. Therefore, patients with
heart failure should be closely monitored to prevent potential bleeding
complications.
Keywords: acenocoumarol, cohort study, heart failure, overanticoagulation,
phenprocoumon.
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Methods
Setting
Data were obtained from the Rotterdam Study and from the
regional outpatient anticoagulation clinic. The Rotterdam
Study is a prospective population-based cohort study in 7983
subjects of 55 years and older and has been approved by the
Medical Ethics Committee of the Erasmus Medical Centre
(Hofman et al, 1991). The baseline examination was conduc-
ted between 1990 and 1993, during which information was
obtained on age, gender, smoking, body mass index (BMI),
medication use, blood pressure and verified history of heart
failure. Participants have been continuously monitored for
major events that occurred during follow-up, including heart
failure, through automated linkage with files from general
practitioners. Information on vital status was also obtained
regularly from municipal health authorities in Rotterdam.
Furthermore, all drug prescriptions dispensed to participants
by automated pharmacies were routinely stored in the
database.
The anticoagulation clinic monitors all inhabitants of
Ommoord with an indication for anticoagulant therapy. The
choice of anticoagulant was made by the physician. The
optimal target range of coumarin anticoagulant therapy, as
recommended by the Federation of Dutch Thrombosis Cen-
ters, lies between 2Æ5 and 3Æ5 INR or between 3Æ0 and 4Æ0 INR,
depending on the indication for treatment. Some patients are
targeted at a level between 2Æ0 and 2Æ5 INR because of
contraindications. Prothrombin times were monitored at
1–6-week intervals by reference to the INR, dependent on
the stability of the anticoagulant level. Doses were adjusted on
the basis of the target range of the INR of the patient by
computerized dose calculations.
Cohort and outcome definition
The study cohort consisted of all participants of the Rotterdam
Study who were treated with acenocoumarol or phenprocou-
mon in the study period between the baseline visit and 1
January 2000 and for whom INR data were available. If a
patient had multiple treatment periods during the study
period, only the first period after the baseline examination was
considered. The cohort included patients on coumarin anti-
coagulants without heart failure, patients on coumarins with
prevalent heart failure at baseline and patients on coumarins
who developed heart failure during the study period (inciden-
tal cases). All cohort members were followed-up as of their
baseline examination for patients without heart failure and for
cases of prevalent heart failure, and from the date of incidental
heart failure for incidental cases until the earliest of an INR
‡6Æ0, death, loss to follow-up, or 1 January 2000. In cases
where the date of incidental heart failure was not during a
treatment period with coumarins, follow-up started at the first
day of the next treatment period and heart failure was classified
as prevalent. The index date was defined as the point in time at
which one of the endpoints occurred for a participant of this
study. The effect of heart failure on the coumarin dosage was
determined by calculating the average weekly dosage per INR
measurement for the subsequent measurements after start of
follow-up. This was carried out separately for prevalent and
incidental cases of heart failure and for the rest of the cohort,
and for both acenocoumarol and phenprocoumon. For the
incidental cases of heart failure, for which the follow-up started
at the date of incidental heart failure, we also studied the
course of the coumarin dosage from the 10th INR measure-
ment preceding this date.
Heart failure assessment
Assessment of prevalent heart failure at baseline has been
described in detail (Mosterd et al, 1999). Cases of incidental
heart failure were obtained by continuously monitoring
participants of the Rotterdam Study for the occurrence of
heart failure during follow-up through automated linkage with
files from general practitioners. All available data on these
events, such as hospital discharge letters and notes from
general practitioners, were copied from the medical records.
Apart from this systematic follow-up procedure, we used
verified hospital discharge diagnoses for case finding, gathered
from all hospitals in the Rotterdam area. The definition of
heart failure was based on the criteria of the European Society
of Cardiology, which include the presence of typical symptoms
of heart failure, such as pulmonary crepitations, and objective
evidence of cardiac dysfunction (Remme & Swedberg, 2001).
Cofactors
The following baseline patient characteristics were considered
as potential determinants for affecting the response of the INR
to coumarin anticoagulants: gender, age, CYP2C9 genotype,
hepatic dysfunction (defined as serum aminotransferases >2·
the upper level of normal), hypoalbuminaemia (£35 g/l),
malignancies, hyperthyroidism, hypertension (systolic blood
pressure ‡140 mmHg and/or diastolic blood pressure
‡90 mmHg or use of antihypertensives) and low dietary
intake of vitamin K (<1 lg/kg/d). In addition, we considered
the type of anticoagulant, the indication for therapy, the target
INR level, the number of visits to the anticoagulation clinic
during the follow-up period, and the use of thiazides or non-
steroidal anti-inflammatory drugs (NSAIDs) on the index date
as potential confounding factors. Separate analyses were
performed for prevalent and incidental cases of heart failure.
Statistical analysis
Allele and genotype proportions were tested for deviations
from Hardy–Weinberg equilibrium (HWE) by using a chi-
squared test. Independent-sample t-tests and Pearson’s chi-
square were used to compare baseline characteristics between
L. E. Visser et al
86 ª 2004 Blackwell Publishing Ltd, British Journal of Haematology, 127, 85–89
prevalent or incidental heart failure cases and patients without
heart failure. Incidence rates of overanticoagulation were
calculated by dividing the number of cases of an INR ‡6Æ0 by
the number of days on a coumarin anticoagulant. The
association between heart failure and overanticoagulation
was evaluated using Cox proportional hazards regression
analysis to estimate relative risks (RR) and 95% confidence
intervals (95%CI). To adjust for potential confounding,
cofactors were included in the model, in addition to age and
gender, if the point estimate changed by >5% upon inclusion
of the cofactor in the model. For missing data on categorical
covariates, we used a missing value indicator, whereas for
missing data on continuous covariates, we used the median
value of the respective value as calculated from the total
sample. To evaluate the effect of incidental heart failure on the
coumarin dosage, a trend test was performed using a linear
regression model with the mean dosage as outcome variable.
For all statistical analyses P < 0Æ05 were considered to be
statistically significant. All statistical analyses were performed
with the Statistical Package for the Social Sciences (spss)
version 11.0.1 (SPSS Inc., Chicago, IL, USA).
Results
A total of 1077 individuals on coumarin anticoagulants were
included in our study population (Table I). The mean age of
these patients was almost 72 years, and 47Æ4% of the patients
were men. All patients were white people. There were 636
patients (59Æ1%) with the wild type CYP2C9 genotype
(CYP2C9*1/*1 homozygotes), and 323 (30Æ0%) with a variant
genotype (one or two of the mutant alleles CYP2C9*2 or
CYP2C9*3). Allele and genotype proportions were in HWE.
There were 915 acenocoumarol-treated patients (85Æ0%), and
162 patients (15Æ0%) who used phenprocoumon. Twenty-five
patients (2Æ3%) were targeted at an INR between 2Æ0 and 2Æ5,
368 patients (34Æ2%) at an INR between 2Æ5 and 3Æ5, and 684
patients (63Æ5%) at an INR between 3Æ0 and 4Æ0. Patients had a
median of 29 INR assessments during a median follow-up
time of 245 days (0Æ7 years).
There were 234 cases of prevalent and 66 cases of incidental
heart failure identified during the study period. Patients with
prevalent heart failure were significantly older and more likely
to be male than patients without heart failure. They were more
often treated with phenprocoumon, were more often targeted
at the highest INR level and had their INR more frequently
measured. Patients with incidental heart failure were signifi-
cantly older, were more often targeted at the highest INR level
and were more likely to have hypoalbuminaemia than patients
without heart failure. Patients without heart failure used
coumarins more often for prophylaxis and treatment of venous
thrombosis, while patients with prevalent and incidental heart
failure had more often an arterial indication for coumarin
anticoagulant therapy.
During the study period, 396 of the 1077 individuals (37%)
had an INR ‡6Æ0. Of the 234 prevalent cases of heart failure,
131 individuals (56%) experienced an INR ‡6Æ0, and of the 66
incidental heart failure cases 32 individuals (48%) were
overanticoagulated. Table II presents relative risk estimates
for the association between prevalent and incidental heart
failure and overanticoagulation. Prevalent and incidental heart
failure were both univariately, and after adjustment for
confounding factors, associated with an increased risk of
overanticoagulation.
Figure 1 shows the mean weekly dosage of acenocoumarol
for the subsequent INR measurements after the start of the
follow-up. Patients with prevalent and incidental heart failure
used lower dosages than patients without heart failure, in spite
of the higher target INR levels for patients with heart failure.
Patients with incidental heart failure had even lower acen-
ocoumarol dose requirements than patients with prevalent
heart failure. As this difference did not disappear in the course
of time, this probably reflects the difference in indication
and target INR level. Similar features were identified for
Table I. Characteristics of the study population.
Variable
Number of patients
(n ¼ 1077)
Gender
Male 511 (47Æ4%)
Female 566 (52Æ6%)
Age [average (SD)] (years) 71Æ8 (7Æ9)
CYP2C9 genotype*
Wild type genotype 636 (59Æ1%)
Variant genotype 323 (30Æ0%)
Type of anticoagulant
Acenocoumarol 915 (85Æ0%)
Phenprocoumon 162 (15Æ0%)
Indication
Prophylaxis venous thrombosis 227 (21Æ1%)
Treatment of venous thrombosis 368 (14Æ0%)
Treatment or prophylaxis of
arterial thrombosis
673 (62Æ4%)
Prosthetic heart valves 25 (2Æ3%)
Target INR level
2Æ0–2Æ5 25 (2Æ3%)
2Æ5–3Æ5 368 (34Æ2%)
3Æ0–4Æ0 684 (63Æ5%)
Time between visits (d ± SD) 11Æ9 ± 16Æ3
Hepatic dysfunction 12 (1Æ1%)
Hypoalbuminaemia 2 (0Æ2%)
Malignancies 123 (11Æ4%)
Hyperthyroidism 37 (3Æ4%)
Hypertension 422 (39Æ2%)
Low intake of vitamin K 16 (1Æ5%)
Use of thiazides§ 4 (0Æ4%)
*Totals do not add up to 100% because of missing genotypes.
CYP2C9*1/*1 homozygotes.
Patients with one or more of the variant alleles CYP2C9*2 or
CYP2C9*3.
§Assessed by reference to the index date.
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phenprocoumon. For patients with incidental heart failure the
decrease in dosage started, on average, at the fifth INR
measurement preceding the incident date and lasted until the
third INR measurement after the incident date. A trend test
revealed a significant dosage decrease between the subsequent
INR measurements of 0Æ23 mg/week for acenocoumarol (P for
trend <0Æ001) and 0Æ34 mg per week for phenprocoumon (P
for trend <0Æ001).
Discussion
The current study identified heart failure as an independent
risk factor for excessive anticoagulation under everyday
circumstances. Patients with heart failure had a 1Æ5-fold to
twofold increased risk of an INR ‡6Æ0. Our results are in
accordance with the study of Penning-van Beest et al (2001),
who found an OR of 1Æ6 (95%CI: 1Æ04–2Æ6) in stable
condition and an OR of 3Æ0 (95%CI: 0Æ8–12Æ0) in case of a
relapse.
This increased coumarin responsiveness is assumed to be the
result of an impairment of liver function resulting from
congestion (Stats & Davison, 1949; Covert, 1952; Killip &
Payne, 1960; O’Reilly & Aggeler, 1970). Patients with heart
failure were noted to have an increased response as hepatic
congestion developed (Killip & Payne, 1960; O’Reilly &
Aggeler, 1970), and the responsiveness decreased on relief of
the congestion by corrective cardiac surgery (Storm & Hansen,
1955) or use of diuretics (Verstraete & Verwilghen, 1980). Our
data also indicate that coumarin responsiveness was already
slowly increasing during the weeks preceding the incidental
heart failure date, probably because of increasing hepatic
congestion. It is speculated that the determinants of increased
coumarin responsiveness might chiefly be pharmacodynamic
(associated with impaired clotting factor synthesis) rather than
pharmacokinetic (associated with decreased hepatic coumarin
clearance) (Bachmann & Shapiro, 1977; Verstraete & Verwilg-
hen, 1980). The hypothrombinaemic effect will be even larger
because of the redistribution of body water in heart failure
patients and consequent accumulation of unbound coumarin
anticoagulant in the vicinity of hepatic receptor sites (Bach-
mann & Shapiro, 1977).
The clinical implication of these findings lies in the
possibility of prevention or early detection of excessive
anticoagulation, and thus of haemorrhagic complications, by
paying special attention to this risk factor when monitoring
anticoagulant therapy. Patients with heart failure should there-
fore be closely monitored for signs of excess anticoagulation
and fluid overload and it should be noted whether patients are
Table II. Relative risks for the association
between heart failure and overanticoagulation.No. Events (n) IR* RRcrude (95%CI) RRadj. (95%CI)
Patients without heart failure 777 233 5Æ19 1Æ00 (reference) 1Æ00 (reference)
Prevalent heart failure 234 131 9Æ82 1Æ84 (1Æ48–2Æ28) 1Æ66 (1Æ33–2Æ07)
Incidental heart failure 66 32 11Æ78 1Æ97 (1Æ36–2Æ86) 1Æ91 (1Æ31–2Æ79)
*The incidence rate is expressed as the number of cases of overanticoagulation per 10 000 d on a
coumarin anticoagulant.
Adjusted for gender, age and target INR level.
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Fig 1. Course of the mean weekly aceno-
coumarol dosage over time. hf, heart failure.
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taking any drugs associated with fluid retention (e.g. vasodi-
lators, NSAIDs).
In our study, selection bias was probably negligible as we
identified all users of oral anticoagulants in a defined
population and because regular INR monitoring makes it
unlikely that cases were missed. In addition, information bias
is not likely as all data on heart failure and coumarin
anticoagulant dosages were recorded similarly without prior
knowledge of our study hypothesis. Potential confounding by
gender, age, CYP2C9 genotype, hepatic dysfunction, hypoal-
buminaemia, malignancies, hyperthyroidism, hypertension,
low dietary intake of vitamin K, type of anticoagulant,
indication for therapy, target INR level, time between the
INR measurements, and use of thiazides and NSAIDs was dealt
with in the multivariate analyses. Use of thiazide diuretics on
the index date was taken into consideration because current
use of these drugs was found to increase the bleeding risk of
oral anticoagulant therapy by 5Æ2% (Launbjerg et al, 1991).
In conclusion, heart failure is an independent risk factor for
overanticoagulation. Patients with heart failure should there-
fore be closely monitored for signs of excess anticoagulation
and fluid overload to prevent potential bleeding complications.
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